Recorded device evidence

TAMPAX(R) V PLASTIC APPLICATOR TAMPONS, UNSCENTED (K113699): indications, design and recorded evidence

The acquired K113699 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 22 selected decisions under primary code HEB. 22 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 30.2, median 84.5, upper quartile 159.8. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K113699 ↗ · this pageTAMPAX(R) V PLASTIC APPLICATOR TAMPONS, UNSCENTED2011-12-16 → 2012-01-1227Special
K252005 ↗Livi Device2025-06-27 → 2026-03-20266Traditional
K253719 ↗Unscented Menstrual Long Applicator Tampon; Unscented Menstrual Cardboard Applicator Tampon; Unscented Menstrual Digital Tampons2025-11-24 → 2025-12-1723Special
K252939 ↗COHITECH ORGANIC COTTON COMPACT APPLICATOR TAMPONS2025-09-15 → 2025-10-0924Special
K252613 ↗Unscented menstrual three-piece applicator tampon2025-08-19 → 2025-09-1931Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K113699 · PDF page 1 ↗ Source 2

TAMPAX®   V       Plastic        Applicator        Tampons,
                                                                                                                 unscented            are           intended     to       be         inserted         into           the    vagina
                                                                                                                 to     absorb           menstrual        fluid.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K113699 · PDF page 1 ↗ Source 2

Unscented            menstrual          tampons      for          absorption        of
                                                                                                                 menstrual          fluid.                        The     tampon           is a conventional
                                                                                                                 design        consisting          of an         absorbent       pledget,           an
                                                                                                                 overwrap,         a withdrawal              cord        and      an         applicator.                     The
                                                                                                                 materials          of construction        are         cotton,         rayon,
                                                                                                                 polypropylene            and        polyester.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K113699 · PDF page 2 ↗ Source 3

Results          of the       Syngyna,         expulsion         force,              and       tampon       withdrawal            cord
         anchor      strength            testing      show      no        change           from       the      predicate             device        and        confirm           that     the
         material         changes          do        not        impact          safety        of the           device.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK113699 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryTAMPAX(R) V PLASTIC APPLICATOR TAMPONS, UNSCENTED [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantThe Procter & Gamble Company [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeHEB [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2012-01-12 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeSpecial [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2011-12-16 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[68921] · record 3eb1c41e8d0626f5f25fe7b97bbbcefce5c1cb9ca087368871c2eb36b68bc508
  • [4] Complete results array / fda-decision-context:K113699 · record whole dataset partition

FDA 510(k) summary — K113699 ↗

Mon, 27 Feb 2012 05:32:15 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 5d65041a30d8d33d68fd63fe03c1ee18017999cb3dd7b7f5b67e40300bd143ef

  • [2] PDF page 1 · record 03f3d2e651a30e73a9bc6c2225075cadc80f9875eb7fb128614059df6f436611
  • [3] PDF page 2 · record a8a3e4fda2a378033763690e8482f1e4324d2a9ccf7998b78b79d5800e7f9c45

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services